Regenerative Medicine Market Segmentation:
Therapy Type Segment Analysis
The cell therapy is projected to garner 25.3% of the market share by 2037, owing to the designation of the Regenerative Medicine Advanced Therapy by the FDA. In 2023, more than 90 cell therapy products were in advanced stages of clinical development, including CAR-T for malignancies associated to hematology. Other than this, in 2024, the FDA has approved 5 CAR-T therapies, including Yescarta, for the treatment of blood cancer. The stem cell transplant lowers the mortality by 41% in various diseases related to the graft vs host.
End User Segment Analysis
The hospitals and clinics segment is anticipated to garner 45.5% of the share by 2037 due to the increasing number of FDA-approved regenerative therapies such as CAR-T and stem cell injections. Hospitals with specialized regenerative medicine centers, such as the Mayo Clinic and the Cleveland Clinic, are gaining popularity among the population. Also, Medicare and Medicaid reimbursements are widely available for the approved therapies. In 2024, the FDA also stated that more than 100 hospitals are offering CAR-T therapies for blood cancer.
Our in-depth analysis of the global regenerative medicine market includes the following segments:
|
Segment |
Subsegment |
|
Type |
|
|
Trade |
|
|
Application |
|
|
Technology |
|
|
End User |
|
